Literature DB >> 9861240

Bradycardia induced by irinotecan: a case report.

T Miya1, R Fujikawa, J Fukushima, H Nogami, Y Koshiishi, T Goya.   

Abstract

Irinotecan chloride (CPT-11) is a new semi-synthetic camptothecin analogue which has encouraging antitumor activity against various malignancies. The major and unique toxicity of CPT-11 is diarrhea. Cardiovascular toxicity is rare and has not been found in clinical trials performed in Japan except for a very few cases of insignificant tachycardiac arrhythmia. We report a case of a 69-year-old man with recurrent colon cancer who suffered from bradycardia induced by infusion of CPT-11. Other toxicities including hematological toxicity and diarrhea were mild. Pharmacokinetic analysis using a limited sampling model revealed that the occurrence of bradycardia did not correlate with the excess of drug exposure. Although all of the cholinergic actions reported in the literature were mild, cardiotoxicity may come to be a clinically significant problem. If the events were examined more thoroughly, the cholinergic effect may be discovered more frequently. To administer CPT-11 safely needs meticulous monitoring not only for hematological toxicity and diarrhea but also for other cholinergic actions including bradycardia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9861240     DOI: 10.1093/jjco/28.11.709

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

Review 1.  Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.

Authors:  Nicole S Klee; Cameron G McCarthy; Patricia Martinez-Quinones; R Clinton Webb
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-09-15

2.  Irinotecan inducing sinus pause bradycardia in a patient with small round cell cancer.

Authors:  Tanveer Ahmad Mir; Ahmed S Yassin; Eric Joseph Denha; Raad Al Shaikhli; Ali Rahim; Sabah Ambreen; Prateek Lohia
Journal:  BMJ Case Rep       Date:  2020-05-31

3.  Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment.

Authors:  Hung-Jun Lin; Tien-Li Liang; Yao-Yuan Chang; Der-Zen Liu; Jia-Yu Fan; Steve R Roffler; Shyr-Yi Lin
Journal:  Pharmaceutics       Date:  2022-06-05       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.